Chemotherapy in the treatment of malignant gliomas

References

• CBTRUS (2005). Statistical report: primary brain tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States, IL, USA (2006).
   Google Scholar
• Lacroix M, bi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery34, 45–60 (1994).
   PubMed Web of Science ®Google Scholar
• Albert FK, Forsting M. Resection and prognosis. J. Neurosurg.98, 225–226 (2003).
   PubMedGoogle Scholar
• Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys.26, 239–244 (1993).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir.148, 269–275 (2006).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med.303, 1323–1329 (1980).
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg.49, 333–343 (1978).
   PubMed Web of Science ®Google Scholar
• Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer47, 649–652 (1981).
   PubMed Web of Science ®Google Scholar
• Lee SW, Fraass BA, Marsh LH et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys.43, 79–88 (1999).
   PubMedGoogle Scholar
• Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol.6, 953–960 (2005).
   PubMedGoogle Scholar
• Narayana A, Yamada J, Berry S et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int. J. Radiat. Oncol. Biol. Phys.64, 892–897 (2006).
   PubMed Web of Science ®Google Scholar
• Knisely JP, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin. N. Am.12, 525–536 (2002).
   PubMed Web of Science ®Google Scholar
• Selker RG, Shapiro WR, Burger P et al. The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery51, 343–355 (2002).
   Google Scholar
• Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int. J. Radiat. Oncol. Biol. Phys.60, 853–860 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J. Clin. Oncol.16, 3851–3857 (1998).
   PubMed Web of Science ®Google Scholar
• Belanich M, Pastor M, Randall T et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res.56, 783–788 (1996).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Eyre HJ, Townsend JJ et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol.16, 3310–3315 (1998).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343, 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J. Clin. Oncol.15, 3121–3128 (1997).
   PubMedGoogle Scholar
• Prados MD, Yung WK, Jaeckle KA et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology6, 44–54 (2004).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WKA, Lamborn K et al. Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99–08). Neuro-oncology6, 385 (2006) (Abstract).
   Google Scholar
• Prados MD, Lamborn KR, Chang S et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology8, 67–78 (2006).
   PubMed Web of Science ®Google Scholar
• Green SB, Byar DP, Walker MD et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep.67, 121–132 (1983).
   PubMedGoogle Scholar
• Solero CL, Monfardini S, Brambilla C et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin. Trials2, 43–48 (1979).
   PubMedGoogle Scholar
• Levin VA, Wara WM, Davis RL et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg.63, 218–223 (1985).
   PubMed Web of Science ®Google Scholar
• Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys.18, 321–324 (1990).
   PubMed Web of Science ®Google Scholar
• Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol.17, 3389–3395 (1999).
   PubMed Web of Science ®Google Scholar
• Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol.19, 509–518 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet359, 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol.17, 2762–2771 (1999).
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol.20, 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Mamelak AN. Locoregional therapies for glioma. Oncology19, 1803–1810 (2005).
   PubMedGoogle Scholar
• Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer65, 287–291 (1992).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res.58, 4363–4367 (1998).
   PubMed Web of Science ®Google Scholar
• Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncology4, 39–43 (2002).
   PubMed Web of Science ®Google Scholar
• Korones DN, ita-Weiss M, Coyle TE et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer97, 1963–1968 (2003).
   PubMed Web of Science ®Google Scholar
• Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. Oncol.27, 33–38 (2004).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol.21, 2305–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol.20, 1383–1388 (2002).
   PubMed Web of Science ®Google Scholar
• Baumann F, Bjeljac M, Kollias SS et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J. Neurooncol.67, 191–200 (2004).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Reardon DA, Friedman AH et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-oncology6, 145–153 (2004).
   PubMedGoogle Scholar
• Reardon DA, Quinn JA, Rich JN et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer104, 1478–1486 (2005).
   PubMed Web of Science ®Google Scholar
• Prados MD, Yung WK, Fine HA et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-oncol.6, 33–37 (2004).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer104, 2473–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology40, 1743–1746 (1990).
   PubMed Web of Science ®Google Scholar
• Newton HB, Bromberg J, Junck L, Page MA, Greenberg HS. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J. Neurooncol.15, 257–263 (1993).
   PubMed Web of Science ®Google Scholar
• Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer64, 2420–2423 (1989).
   PubMed Web of Science ®Google Scholar
• Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a Phase II study. J. Clin. Oncol.9, 860–864 (1991).
   PubMed Web of Science ®Google Scholar
• Poisson M, Pereon Y, Chiras J, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J. Neurooncol.10, 139–144 (1991).
   PubMed Web of Science ®Google Scholar
• Prados MD, Warnick RE, Mack EE et al. Intravenous carboplatin for recurrent gliomas. A dose-escalating Phase II trial. Am. J. Clin. Oncol.19, 609–612 (1996).
   PubMed Web of Science ®Google Scholar
• Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol.27, 149–155 (1996).
   PubMed Web of Science ®Google Scholar
• Tirelli U, D'Incalci M, Canetta R et al. Etoposide (VP-16–213) in malignant brain tumors: a Phase II study. J. Clin. Oncol.2, 432–437 (1984).
   PubMed Web of Science ®Google Scholar
• Finn GP, Bozek T, Souhami RL, Slevin ML, Thomas DG. High-dose etoposide in the treatment of relapsed primary brain tumors. Cancer Treat. Rep.69, 603–605 (1985).
   PubMedGoogle Scholar
• Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol.17, 1516–1525 (1999).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Filka E, Kuhn J et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer97, 2381–2386 (2003).
   PubMed Web of Science ®Google Scholar
• Raymond E, Fabbro M, Boige V et al. Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol.14, 603–614 (2003).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gilbert MR, Supko JG et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97–11. Neuro-oncol.6, 21–27 (2004).
   Google Scholar
• Prados M, Lamborn K, Yung WK et al. A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology8(2), 189–193 (2006).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncology22, 4779–4786 (2004).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Quinn JA, Rich JN et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncol.6, 134–144 (2004).
   PubMed Web of Science ®Google Scholar
• Yung WA, Lieberman FS, Wen P et al. Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) Phase II study. J. Clin. Oncol.23, (2005) (Abstract).
   PubMedGoogle Scholar
• Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res.2, 1931–1935 (1996).
   PubMed Web of Science ®Google Scholar
• See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-oncology6, 253–258 (2004).
   PubMedGoogle Scholar
• Puduvalli VK, Yung WK, Hess KR et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium study. J. Clin. Oncol.22, 4282–4289 (2004).
   PubMed Web of Science ®Google Scholar
• Couldwell WT, Hinton DR, Surnock AA et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin. Cancer Res.2, 619–622 (1996).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol.56, 703–708 (1999).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Ermani M, Turazzi S et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J. Clin. Oncol.17, 645–650 (1999).
   PubMed Web of Science ®Google Scholar
• Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J. Neurooncol.51, 41–45 (2001).
   PubMed Web of Science ®Google Scholar
• Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol.54, 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol.21, 2299–2304 (2003).
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol.18, 708–715 (2000).
   PubMed Web of Science ®Google Scholar
• Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr. Oncol. Rep.8, 58–70 (2006).
   PubMedGoogle Scholar
• Cloughesy TF, Kuhn J, Robins HI et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol.23, 6647–6656 (2005).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Kuhn J, Wen P et al. Two Phase II trials of R115777 (Zarnestra) in patients with recurrent glioblastoma multiforme (GBM): a comparison of patients on enzyme-inducing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: a North American Brain Tumor Consortium (NABTC) report. Neuro-oncology5 (2003) (Abstract).
   Google Scholar
• Gilbert MR, Hess K, Gaupp P et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), tipifarnib (Zarnestra, R115777) in recurrent glioblastoma: a dose and schedule intensive regimen. Neuro-oncology6, 375 (2004) (Abstract).
   Google Scholar
• Katz A, Barrios CH, Abramoff R, Simon SD, Tabacof J, Gansi RC. Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy. J. Clin. Oncol.23, (2004) (Abstract 1542).
   Google Scholar
• Raymond E, Brandes AA, van Oosterom A et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC. NDDG/BTG Intergroup Study. J. Clin. Oncol.22, 383 (2006) (Abstract).
   Google Scholar
• van den Bent M, Brandes A, Frenay M et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. J. Clin. Oncol.22(16 Suppl.) (2005) (Abstract 1517).
   Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16, 1702–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol.23, 9359–9368 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22, 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman FS, Cloughesy T, Fine H et al. NABTC Phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J. Clin. Oncol.22(14 Suppl.) 1510 (2004) (Abstract 1510).
   PubMedGoogle Scholar
• Uhm JH, Ballman KV, Giannini C et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 1505).
   Google Scholar
• Raizer JJ, Abrey LE, Wen P et al. A Phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 1502).
   Google Scholar
• Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: Interim results. J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 1558).
   Google Scholar
• Yung A, Vredenburgh J, Cloughesy T et al. Erlotinib HCL for glioblastoma multiforme in first relapse, a Phase II trial. J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 1555).
   PubMedGoogle Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Razier JR et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from north american brain tumor consortium trials 01–03 and 00–01. Clin. Cancer Res.11, 7841–7850 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs23, 357–361 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs22, 427–435 (2004).
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. World Federaton of Neuro-oncology (2005) (Abstract 342).
   Google Scholar
• Yung WKA, Friedman H, Conrad C et al. A Phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proc. Am. Soc. Clin. Oncol.23 (2003) (Abstract 395).
   Google Scholar
• Reardon D, Cloughesy T, Conrad C et al. A Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 3063).
   Google Scholar
• Reardon D, Friedman H, Yung WKA et al. A Phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol.22(14 Suppl.) (2004) (Abstract 1513).
   PubMedGoogle Scholar
• Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res.63, 8930–8938 (2003).
   PubMed Web of Science ®Google Scholar
• Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther.4, 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol.23, 360–364 (1988).
   PubMed Web of Science ®Google Scholar
• Cairncross G, MacDonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12, 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg.76, 741–745 (1992).
   PubMed Web of Science ®Google Scholar
• Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery32, 365–370 (1993).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Childs BH, Paleologos N et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncology8(2), 183–188 (2006).
   PubMedGoogle Scholar
• Abrey LE, Childs BH, Paleologos N et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J. Neurooncol.65, 127–134 (2003).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90, 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol.18, 636–645 (2000).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology57, 340–342 (2001).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol.14, 599–602 (2003).
   PubMed Web of Science ®Google Scholar
• Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol.19, 2449–2455 (2001).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol.21, 2525–2528 (2003).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Seifeheld W, Shaw E et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94–02. J. Clin. Oncol.22(16 Suppl.) (2004) (Abstract 1500).
   Google Scholar
• van den Bent M, Delattre J, Brandes A et al. First analysis of EORTC trial 26951, a randomized Phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Proc. Am. Soc. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 1503).
   Google Scholar
• Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG. Salvage chemotherapy for oligodendroglioma. J. Neurosurg.85, 597–601 (1996).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J. Neurooncol.59, 157–163 (2002).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J. Clin. Oncol.24, 1246–1252 (2006).
   PubMed Web of Science ®Google Scholar